Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MRK Stock Forecast 2026-2027
$119.05
Current Price
$294.03B
Market Cap
Buy 19
Hold 10
Sell 0
Wall St Analyst Ratings
Distance to MRK Price Targets
+26.0%
To High Target of $150.00
+13.4%
To Median Target of $135.00
-16.0%
To Low Target of $100.00
MRK Price Momentum
-0.5%
1 Week Change
+6.9%
1 Month Change
+47.0%
1 Year Change
+13.1%
Year-to-Date Change
-4.9%
From 52W High of $125.14
+55.3%
From 52W Low of $76.66
📊 TOP ANALYST CALLS
Did MRK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Merck is one of their latest high-conviction picks.
Latest MRK Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, MRK has a bullish consensus with a median price target of $135.00 (ranging from $100.00 to $150.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $119.05, the median forecast implies a 13.4% upside. This outlook is supported by 19 Buy, 10 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRK Analyst Ratings
19
Buy
10
Hold
0
Sell
MRK Price Target Range
Low
$100.00
Average
$135.00
High
$150.00
Current: $119.05
Latest MRK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2026 | Citigroup | Geoff Meacham | Neutral | Reinstates | $125.00 |
| May 1, 2026 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $145.00 |
| Apr 13, 2026 | UBS | Buy | Maintains | $N/A | |
| Apr 6, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Mar 30, 2026 | RBC Capital | Outperform | Reiterates | $N/A | |
| Mar 20, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Mar 12, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 25, 2026 | RBC Capital | Outperform | Initiates | $N/A | |
| Feb 20, 2026 | Barclays | Overweight | Initiates | $N/A | |
| Feb 9, 2026 | Freedom Broker | Hold | Maintains | $N/A | |
| Feb 6, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Feb 4, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Feb 4, 2026 | Cantor Fitzgerald | Neutral | Maintains | $N/A | |
| Feb 4, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Jan 27, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Jan 20, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| Jan 8, 2026 | Wolfe Research | Outperform | Upgrade | $N/A | |
| Jan 7, 2026 | UBS | Buy | Maintains | $N/A | |
| Jan 7, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Dec 18, 2025 | BMO Capital | Outperform | Upgrade | $N/A |
Merck & Co., Inc. (MRK) Competitors
The following stocks are similar to Merck based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Merck & Co., Inc. (MRK) Financial Data
Merck & Co., Inc. has a market capitalization of $294.03B with a P/E ratio of 33.5x. The company generates $65.77B in trailing twelve-month revenue with a 13.6% profit margin.
Revenue growth is +4.9% quarter-over-quarter, while maintaining an operating margin of +38.6% and return on equity of +18.9%.
Valuation Metrics
Market Cap
$294.03B
Enterprise Value
$337.50B
P/E Ratio
33.5x
PEG Ratio
-0.2x
Price/Sales
4.5x
Growth & Margins
Revenue Growth (YoY)
+4.9%
Gross Margin
+74.2%
Operating Margin
+38.6%
Net Margin
+13.6%
EPS Growth
+4.9%
Financial Health
Cash/Price Ratio
+1.9%
Current Ratio
1.3x
Debt/Equity
106.9x
ROE
+18.9%
ROA
+12.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Merck & Co., Inc. (MRK) Business Model
About Merck & Co., Inc.
What They Do
Leading global healthcare company specializing in pharmaceuticals.
Business Model
The company generates revenue through the research, development, and commercialization of innovative pharmaceuticals and vaccines. Its diverse product portfolio includes key oncology drugs and a range of vaccines that cater to various health needs, thus addressing both acute and chronic health conditions.
Additional Information
Founded in 1891 and headquartered in Rahway, New Jersey, the company has established a significant presence in the biopharmaceutical sector, focusing on therapeutic areas such as oncology, vaccines, and immunology. Merck & Co., Inc. plays a crucial role in advancing treatments for serious diseases and promoting preventive health measures worldwide.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
73,000
CEO
Mr. Robert M. Davis J.D.
Country
United States
IPO Year
1970
Website
www.merck.comMerck & Co., Inc. (MRK) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines?
BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.
Jun 12, 2026
By Zacks Equity Research
Analyst Blog
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Jun 12, 2026
By Zacks Equity Research
Fundamental Analysis
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the closing of the recent trading day, Merck (MRK) stood at $120.76, denoting a +1.4% move from the preceding trading day.
Jun 11, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Merck Animal Health to Acquire TARGAN
4 days ago
Quick Summary
Merck Animal Health has agreed to acquire TARGAN, a developer of poultry biodevice solutions, enhancing its offerings in the sector. The purchase price remains undisclosed.
Why It Matters
Merck's acquisition of TARGAN strengthens its position in the poultry market, potentially enhancing revenue streams and innovation in animal health, which may positively impact MRK's stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Merck (MRK) is currently attracting significant attention from Zacks.com users, indicating potential interest and volatility in the stock.
Why It Matters
Increased interest in Merck (MRK) among Zacks.com users may indicate potential for stock movement, influencing trading decisions and market sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Merck (MRK) closed at $120.76, reflecting a 1.4% increase from the previous trading day.
Why It Matters
Merck's 1.4% gain signals positive market sentiment, potentially boosting investor confidence and highlighting strong performance relative to peers.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Wall Street analysts' recommendations significantly influence investor decisions on buying, selling, or holding stocks, impacting stock prices when ratings change.
Why It Matters
Analyst ratings directly influence stock prices and investor decisions, making them crucial for market sentiment and investment strategies. Changes can lead to significant volatility.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
The FDA has approved KEYTRUDA® and KEYTRUDA QLEXTM, in combination with WELIREG®, for adjuvant treatment in specific patients with clear cell renal cell carcinoma (ccRCC).
Why It Matters
FDA approval of KEYTRUDA and WELIREG for ccRCC enhances Merck's oncology portfolio, potentially boosting sales and market share, positively impacting $MRK stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Healthcare remains a defensive sector with steady demand, presenting differentiated investment opportunities amid the popularity of AI and space themes.
Why It Matters
Healthcare's stability amid economic fluctuations presents a reliable investment opportunity, contrasting with the volatility of AI and space sectors. This could attract risk-averse investors.
Source: ETF Trends
Market Sentiment:
Positive
Frequently Asked Questions About MRK Stock
What is Merck & Co., Inc.'s (MRK) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Merck & Co., Inc. (MRK) has a median price target of $135.00. The highest price target is $150.00 and the lowest is $100.00.
Is MRK stock a good investment in 2026?
According to current analyst ratings, MRK has 19 Buy ratings, 10 Hold ratings, and 0 Sell ratings. The stock is currently trading at $119.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRK stock?
Wall Street analysts predict MRK stock could reach $135.00 in the next 12 months. This represents a 13.4% increase from the current price of $119.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Merck & Co., Inc.'s business model?
The company generates revenue through the research, development, and commercialization of innovative pharmaceuticals and vaccines. Its diverse product portfolio includes key oncology drugs and a range of vaccines that cater to various health needs, thus addressing both acute and chronic health conditions.
What is the highest forecasted price for MRK Merck & Co., Inc.?
The highest price target for MRK is $150.00 from at , which represents a 26.0% increase from the current price of $119.05.
What is the lowest forecasted price for MRK Merck & Co., Inc.?
The lowest price target for MRK is $100.00 from at , which represents a -16.0% decrease from the current price of $119.05.
What is the overall MRK consensus from analysts for Merck & Co., Inc.?
The overall analyst consensus for MRK is bullish. Out of 4 Wall Street analysts, 19 rate it as Buy, 10 as Hold, and 0 as Sell, with a median price target of $135.00.
How accurate are MRK stock price projections?
Stock price projections, including those for Merck & Co., Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2026 3:26 AM UTC